Methods for the design of estrogen receptor ligands

Details Methods for the design of estrogen receptor ligands Methods for the design of estrogen receptor ligands

2006-01-18

2009-06-30

Noakes, Suzanne M. (Department: 1656)

Data processing: structural design, modeling, simulation, and em

Simulating nonelectrical device or system

Biological or biochemical

C702S019000, C702S027000

Reexamination Certificate

active

07555415

ABSTRACT:
Estrogen receptor ligands, estrogen receptor polypeptide/ligand complexes, crystals of estrogen receptor polypeptide/ligand complexes, and related methods and software systems are disclosed.

REFERENCES:
patent: 2004/0167155 (2004-08-01), Molinari et al.
patent: WO 98/56812 (1998-12-01), None
patent: WO 2004/031159 (2004-04-01), None
McPherson, A. Current Approaches to Macromolecular Crystallization. European Journal of Biochemistry. 1990. vol. 189, pp. 1-23.
Kundrot, C.E. Which Strategy for a Protein Crystallization Project? Cellular Molecular Life Science. 2004. vol., 61, pp. 525-536.
Cudney R. Protein Crystallization and Dumb Luck. The Rigaku Journal. 1999. vol. 16, No. 1, pp. 1-7.
Ginalski et al., Comparative Modeling for Protein Structure Prediction. Current Opinion in Structural Biololgy, 2006. vol. 16, pp. 172-177.
Goodsell et al., Journal of Molecular Recognition, 1996, vol. 9, pp. 1-5.
Böhm et al., Journal of Computer-Aided Molecular Design, 1992, vol. 6, pp. 61-78.
Dean et al. BioEssays, 1994, 16(9):683-687.
Egner et al., “Different Ligands-Different Receptor Conformations: Modeling of thehERα LBD in Complex with Agonists and Antagonists”Med. Res. Reviews21(6):523-539 (2001).
Klebe, “Recent developments in structure-based drug design”J. Mol. Med. 78:269-281 (2000).
Olivier et al., “Raloxifene-induced myeloma cell apoptosis: a study of nuclear factor-kappaB inhibition and gene expression signature,”Mol. Pharmacol. 69:1615-1623 (2006) (Abstract only).
Somjen et al., ““Non-hypercalcemic” analogs of 1α,25 dihydrozy vitamin D augment the induction of creatine kinase B by estrogen and selective estrogen receptor moduclators (SERMS) in osteolbast-like cells and rat skeletal organs”J. Steroid Biochem. &Mol. Biol. 72:79-88 (2000).
Wurtz et al., “Three-Dimensional Models of Estrogen Receptor Ligand Binding Domain Complexes, Based on Related Crystal Structures and Mutational and Structure-Activity Relationship Data”J. Med. Chem. 41:1803-1814 (1998).
Brzozowski et al., “Molecular basis of agonism and antagonism in the oestrogen receptor”Nature389:753-758 (1997).
Shiau et al., “The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen”Cell95:927-937 (1998).
Brzozowski et al., “Molecular basis of agonism and antagonism in the oestrogen receptor”Nature389:753-758 (1997).
Kim et al., “Estrogen Receptor Ligands. II. Discovery of Benzoxathiins as Potent, Selective Estrogen Receptor α Modulators”J. Med. Chem. 47(9):2171-2175 (2004).
Kong et al., “Structure and mechanism of the oestrogen receptor”Biochem. Soc. Transactions31(1):56-59 (2002).
Leduc et al., “Helix-stabilized cyclic peptides as selective inhibitors of steroid receptor-coactivator interactions”PNAS100(20):11273-11278 (2003).
Ruff et al., “Estrogen receptor transcription and transactivation Structure-function relationship in DNA- and ligand-binding domains of estrogen receptors”Breast Cancer Res. 2:353-359 (2000).
Shiau et al., “Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism”Nature Structural Biol. 9(5):359-363 (2002).
Shiau et al., “The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen”Cell95:927-937 (1998).
Um et al., “Synthesis of Novel Quinolinecarboxamide Derivatives with Estrogenic Activity”Bull. Korean Chem. Soc. 24(5):677-680 (2003).
Waernmark et al., “Interaction of Transcriptional Intermediary Factor 2 Nuclear Receptor Box Peptides with the Coactivator Binding Site of Estrogen Receptor α”J. biol. Chem. 277(24):21862-21868 (2002).

Affiliated with

Also associated with

Rating

Methods for the design of estrogen receptor ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for the design of estrogen receptor ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for the design of estrogen receptor ligands will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4062511